Biomea Fusion, Inc. filings document the regulatory disclosures of a Nasdaq-listed clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic diseases. Its 8-K reports furnish operating and financial results, Regulation FD corporate presentations, clinical-program updates, and capital-structure information for its common stock.
The company’s proxy materials cover annual meeting voting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. These filings frame Biomea’s disclosures around icovamenib, BMF-650, pipeline development, financing needs, governance, and public-company reporting obligations.
Biomea Fusion, Inc. announced preliminary Phase 1 GLP-131 results for BMF-650, an investigational oral GLP-1 receptor agonist. In outpatient Cohorts 1–4, mean Day 29 weight reduction ranged from 1.5% to 3.2%, versus 0.1% for pooled placebo; at doses of 200 mg or higher, mean weekly reduction was approximately 0.97 kg.
Cohort 5 participants received 200 mg once daily for one week, then 400 mg once daily for three weeks; mean Day 29 reduction was 6.1% (6.2 kg), about 1.55 kg per week. Conducted under confinement, Cohort 5 also showed similar reduction in its two placebo participants, who consumed approximately 33% of the 2,100 kcal/day food provided. Biomea said confinement appeared to affect eating behavior and Cohort 5 should be interpreted separately.
Across 40 active-dose participants, all treatment-emergent adverse events were mild or moderate; there were no severe or serious events or TEAE-related dose modifications or study discontinuations. Biomea said these preliminary results reflect four weeks of treatment and additional analysis is ongoing. Further clinical development will require longer-term toxicology studies, and Biomea intends to continue this work while positioning BMF-650 for a strategic partnership.
Biomea Fusion, Inc. (BMEA) has filed a preliminary prospectus supplement for an underwritten offering of common stock and, for certain investors, pre-funded warrants to purchase common stock, under its existing $300.0 million shelf registration. Konik Capital Partners, a division of T.R. Winston & Co., will act as sole underwriter and receive underwriter warrants equal to 7% of the shares sold, exercisable at 250% of the public offering price.
The company has granted the underwriter a 30-day option to purchase up to 15% additional shares of common stock. As of June 30, 2026, Biomea Fusion had 72,483,852 shares outstanding, with significant additional potential equity from options, warrants and an at-the-market program. The company warns investors about immediate and substantial dilution and potential future dilution from other equity issuances.
Net proceeds, together with existing cash, are intended to fund Phase II development of icovamenib in type 1 and type 2 diabetes, regulatory engagement to start registrational studies, and continued clinical development of oral GLP‑1 receptor agonist BMF‑650 for obesity and diabetes, as well as other general corporate purposes.
Biomea Fusion, Inc. (BMEA) reports an update to the anticipated timing of topline results from its ongoing Phase I GLP-131 trial of BMF-650 in obese, otherwise healthy volunteers. The topline data are now expected in October 2026, adjusting the company’s prior expectations for when initial results will be available.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, reported Q2 2026 results showing continued losses but lower spending. For the three months ended June 30, 2026, the company recorded a net loss of $8.3 million compared with $20.7 million a year earlier, with no product revenue.
Operating expenses fell to $12.8 million, driven by reduced research and development spending of $9.1 million (down from $16.6 million) and general and administrative costs of $3.6 million (down from $4.7 million), reflecting lower headcount and facilities costs. Net cash used in operating activities for the first half of 2026 was $21.7 million.
Liquidity remains tight. As of June 30, 2026, cash, cash equivalents and restricted cash totaled $35.2 million, and management expects this to fund operations only into the second quarter of 2027. The company states there is substantial doubt about its ability to continue as a going concern without additional financing. Biomea continues to advance icovamenib in Phase II trials for type 2 diabetes and BMF-650 in a Phase I obesity study while seeking to partner its oncology asset BMF-500.
Biomea Fusion, a clinical-stage diabetes and obesity medicines company, reported results for the quarter ended June 30, 2026 and highlighted progress across its pipeline. Two Phase II COVALENT-211 and -212 trials of icovamenib in Type 2 diabetes are enrolling, with 26-week data expected in the first and second quarters of 2027, and a Phase I GLP-131 obesity trial of BMF-650 is on track to deliver initial 28-day weight reduction data in the third quarter of 2026. The company is planning a Phase II trial in recently diagnosed Type 1 diabetes and initiated a research collaboration with the University of Leicester to test icovamenib plus semaglutide in obesity. Cash runway is projected into the second quarter of 2027.
For the second quarter of 2026, net loss attributable to common stockholders was $8.3 million versus $20.7 million a year earlier, and first-half net loss was $20.7 million versus $50.0 million. R&D expenses fell to $9.1 million from $16.6 million, and G&A expenses to $3.6 million from $4.7 million, largely reflecting reduced headcount and lower external and facility costs. Cash, cash equivalents and restricted cash totaled $35.2 million as of June 30, 2026.
Biomea Fusion, Inc. director Elizabeth Faust received a grant of stock options covering 196,299 shares of common stock at an exercise price of $1.15 per share. These options vest in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholder meeting, contingent on her continued service. Following this grant, she holds 196,299 derivative securities directly.
Biomea Fusion, Inc. director Eric Aguiar received a grant of stock options covering 196,299 shares of common stock. The options have an exercise price of $1.15 per share and expire on June 9, 2036.
The options were granted as compensation rather than an open-market purchase. They vest in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholder meeting, provided Aguiar continues to serve the company through that vesting date.
Biomea Fusion, Inc. director Ray Sumita received a stock option grant covering 196,299 shares of common stock. The option has an exercise price of $1.1500 per share and expires on June 9, 2036. These options vest in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholder meeting, subject to Sumita’s continued service. Following this compensation-related award, Sumita holds 196,299 derivative securities directly, with no open-market buying or selling reported.
Biomea Fusion, Inc. director Julianne Averill reported receiving a stock option grant under the company’s equity plan. The option covers 173,711 shares of Common Stock at an exercise price of $1.15 per share and expires on June 9, 2036.
The filing states this is a compensation-related award, not an open-market purchase or sale. According to the vesting terms, all underlying shares will vest in full on the earlier of one year from the grant date or immediately before the next annual stockholder meeting, provided she continues serving the company through that date.
Biomea Fusion, Inc. reported the results of its Annual Meeting of Stockholders held on June 10, 2026. Holders of 72,299,440 common shares were entitled to vote, and 43,924,456 shares were present or represented by proxy.
Stockholders elected Rainer (Ramses) Erdtmann and Eric Aguiar as Class II directors to serve until the 2029 Annual Meeting or until successors are elected and qualified. Their elections included broker non-votes totaling 20,107,625 shares.
Stockholders also ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 40,209,966 votes for, 3,561,734 against, and 152,756 abstentions.